Phase 3 trial data confirm efficacy and safety profile of R21/Matrix-M malaria vaccine in African children
Express Pharma
FEBRUARY 1, 2024
The R21/Matrix-M vaccine was designed in 2011 as a potential improvement on the RTS, S/AS01 malaria vaccine designed in the 1980s. A phase II trial in Burkina Faso, reporting in 2021, was the first to show that R21/Matrix-M could reach the WHO-specified target of 75 per cent efficacy in African children.
Let's personalize your content